Trial · NCT03520036
Results by group36
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 36
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in Average Daily Time (Minutes) to First Prodromal Symptom Associated With Sunlight Exposure Between Hour Post Sunrise and 1 Hour Pre-Sunset at Week 16. | MT-7117 Low Dose | 74.7 | Standard Deviation 76.8 | Minutes | |
| Change From Baseline in Average Daily Time (Minutes) to First Prodromal Symptom Associated With Sunlight Exposure Between Hour Post Sunrise and 1 Hour Pre-Sunset at Week 16. | MT-7117 High Dose | 92.4 | Standard Deviation 100 | Minutes | |
| Change From Baseline in Average Daily Time (Minutes) to First Prodromal Symptom Associated With Sunlight Exposure Between Hour Post Sunrise and 1 Hour Pre-Sunset at Week 16. | Placebo | 21.0 | Standard Deviation 63.4 | Minutes | |
| Change From Baseline in Average Daily Duration (Minutes) of Sunlight Exposure Between 1 Hour Post Sunrise and 1 Hour Pre-Sunset Without Prodromal Symptoms at Week 16 | MT-7117 Low Dose | 72.6 | Standard Deviation 76.2 | Minutes | |
| Change From Baseline in Average Daily Duration (Minutes) of Sunlight Exposure Between 1 Hour Post Sunrise and 1 Hour Pre-Sunset Without Prodromal Symptoms at Week 16 | MT-7117 High Dose | 86.1 | Standard Deviation 83.9 | Minutes | |
| Change From Baseline in Average Daily Duration (Minutes) of Sunlight Exposure Between 1 Hour Post Sunrise and 1 Hour Pre-Sunset Without Prodromal Symptoms at Week 16 | Placebo | 19.9 | Standard Deviation 63.2 | Minutes | |
| Change From Baseline in Average Daily Mean Duration (Minutes) of Sunlight Exposure Between 1 Hour Post Sunrise and 1 Hour Pre-Sunset Without Prodromal Symptoms at Week 16 | MT-7117 Low Dose | 70.2 | Standard Deviation 73.4 | Minutes | |
| Change From Baseline in Average Daily Mean Duration (Minutes) of Sunlight Exposure Between 1 Hour Post Sunrise and 1 Hour Pre-Sunset Without Prodromal Symptoms at Week 16 | MT-7117 High Dose | 59.3 | Standard Deviation 85.2 | Minutes | |
| Change From Baseline in Average Daily Mean Duration (Minutes) of Sunlight Exposure Between 1 Hour Post Sunrise and 1 Hour Pre-Sunset Without Prodromal Symptoms at Week 16 | Placebo | 12.8 | Standard Deviation 46.9 | Minutes | |
| Total Number of Sunlight Exposure Episodes With Prodromal Symptoms During 16-Week Double-Blind Treatment Period | MT-7117 Low Dose | 8.6 | Standard Deviation 9.3 | sunlight exposure episodes | |
| Total Number of Sunlight Exposure Episodes With Prodromal Symptoms During 16-Week Double-Blind Treatment Period | MT-7117 High Dose | 7.7 | Standard Deviation 6.6 | sunlight exposure episodes | |
| Total Number of Sunlight Exposure Episodes With Prodromal Symptoms During 16-Week Double-Blind Treatment Period | Placebo | 11.1 | Standard Deviation 13.3 | sunlight exposure episodes | |
| Change From Baseline in Average Daily Mean Intensity of Prodromal Symptoms During 16-week Double-blind Treatment Period in 11-point Likert Scale | MT-7117 Low Dose | Baseline | 2.0 | Standard Deviation 1.1 | score on a scale |
| Change From Baseline in Average Daily Mean Intensity of Prodromal Symptoms During 16-week Double-blind Treatment Period in 11-point Likert Scale | MT-7117 High Dose | Baseline | 2.1 | Standard Deviation 0.9 | score on a scale |
| Change From Baseline in Average Daily Mean Intensity of Prodromal Symptoms During 16-week Double-blind Treatment Period in 11-point Likert Scale | Placebo | Baseline | 2.0 | Standard Deviation 1.1 | score on a scale |
| Change From Baseline in Average Daily Mean Intensity of Prodromal Symptoms During 16-week Double-blind Treatment Period in 11-point Likert Scale | MT-7117 Low Dose | Week 16 | 1.7 | Standard Deviation 1.1 | score on a scale |
| Change From Baseline in Average Daily Mean Intensity of Prodromal Symptoms During 16-week Double-blind Treatment Period in 11-point Likert Scale | MT-7117 High Dose | Week 16 | 2.4 | Standard Deviation 1.7 | score on a scale |
| Change From Baseline in Average Daily Mean Intensity of Prodromal Symptoms During 16-week Double-blind Treatment Period in 11-point Likert Scale | Placebo | Week 16 | 2.4 | Standard Deviation 1.4 | score on a scale |
| Change From Baseline in Average Daily Duration (Minutes) of Prodromal Symptoms at 16-Week Double-Blind Treatment Period | MT-7117 Low Dose | 55.3 | Standard Deviation 321.0 | Minutes | |
| Change From Baseline in Average Daily Duration (Minutes) of Prodromal Symptoms at 16-Week Double-Blind Treatment Period | MT-7117 High Dose | 111.0 | Standard Deviation 466.1 | Minutes |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03520036/results